Page 1257 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1243

structures of, 350f guanethidine, 181–182, 191t peripheral metabolism of, 688, 689f
toxicities of, 351–352 reserpine, 179t, 182, 191t pharmacokinetics of, 689t, 690
chemistry of, medicinal, 142–155 adrenoceptor antagonist drugs, T 4 , 687, 689t, 690–692, 701t. See also
clinical uses of, 151–153, 154t 156–172 Thyroid drugs
additional, 153 α-adrenoceptor blockers, 184 biosynthesis of, 688, 688f
anaphylaxis, 152–153 b-adrenoceptor blockers, 179t, 182–183. contraceptives on, female hormonal, 733
cardiovascular See also b-receptor antagonist effects of, 691, 693f
cardiac, 152 drugs in hypothalamic-pituitary-thyroid axis,
hypotension, acute, 151 esmolol, 183 689, 691f
hypotension, chronic orthostatic, labetalol, carvedilol, and nebivolol, mechanism of action of, 690–691, 693f
152 183, 192t peripheral metabolism of, 688, 689f
shock, 151 metoprolol and atenolol, 179t, 183 pharmacokinetics of, 689t, 690
vasoconstriction, local, 152 nadolol, carteolol, betaxolol, Tachykinins, 313, 377t. See also specific types
CNS, 153 bisoprolol, 183 Tachyphylaxis, 38
genitourinary, 153 pindolol, acebutolol, and penbutolol, Tacrine, 120, 1063
heart failure, 226t 183 Tacrolimus (FK 506), 986, 1074–1075
ophthalmic, 153 propranolol, 179t, 182–183 Tadalafil, 200b
pulmonary, 152 centrally acting, 179t, 179–180, 191t Taenia saginata
definition of, 137 clonidine, 179t, 179–181 niclosamide for, 943
direct-acting, 137–138, 141t, 144f, 146f, guanabenz and guanfacine, 180 praziquantel for, 945
149, 149f. See also specific types methyldopa, 179t, 180 Taenia solium
endogenous catecholamines, 146f, 146t, preparations of, 193t niclosamide for, 943
148–149 ganglion-blocking agents, 181 praziquantel for, 945
indirect-acting, 137–138, 150–151 prazosin, 179t Tamoxifen
amphetamine-like, 97f, 144f, 150 prazosin and, 184 breast cancer treated with, 971
catecholamine reuptake inhibitors, Synapses description of, 35, 737f, 737–738
143f, 151 autonomic, 93 Tamsulosin, 157f, 159t, 159–160, 170t.
mixed, noradrenergic transmitter central nervous system, 370–371, 371f See also Adrenoceptor antagonist
release by, 95 peripheral, 102t drugs
mixed-acting sympathomimetics, Synaptic potential, 370–371, 371f Tangier disease, 631
144f, 150 Synaptic transmitters, 29–30. See also Tapentadol, 570, 572t, 573t
noradrenergic transmitter release by, 95 Neurotransmitters Tapeworms
mixed-acting, 144f, 150 Synaptobrevin, 94 niclosamide for, 943
molecular pharmacology of, 138–142 Synaptosomal nerve-associated proteins praziquantel for, 944–945
norepinephrine transporter in, 142, 143f (SNAPs), 90, 94f Tar compounds, dermatologic, 1082
organ system effects of Synaptotagmin, 95 Tardive akathisia, 506
cardiovascular, 101t, 102f, 144–147, Syndrome of inappropriate ADH secretion Tardive dyskinesia, 506, 522
146t (SIADH), 268 Tardive dystonia, 506
beta-receptor activation in, 145, Synechia, 130 Target, drug, 10–11. See also specific drugs
146f, 146t, 147 Synergism, in antimicrobial drug, 912–913 Target concentration, 49, 51–52
dopamine-receptor activation in, 147 Synergistic killing, 828 drug examples of, 43t–44t
α 1 -receptor activation in, 144–145, Synergy studies, antimicrobial, 906 pharmacodynamic variables in, 52
146f, 146t, 147f Synonymous SNPs, 75t pharmacokinetic variables in, 51–52
α 2 -receptor activation in, 145 Syntaxin, 95 rational dosage regimen based on, 49–51
noncardiac, 145t, 147–148 Synucleinopathy, 493 loading dose in, 50–51, 51f
in OTC agents, 1129t Systolic heart failure. See also Heart failure maintenance dose in, 50, 50b, 51f
preparations available, 155t description of, 212 strategy in, 52b
specific drugs in, 148–151 diastolic heart failure versus, 222t TAS-102, 959–960
structure in, 142–144, 143f Systolic hypertension, 174 Tasimelteon, 287b, 382, 384b, 394t
substitution on alpha carbon in, Tau protein, 1062
143–144, 144f T Tavaborole, 1072
substitution on amino group in, 143 T 3 , 687, 690–692, 701t. See also Thyroid Taxanes and other anti-microtubule drugs,
substitution on benzene ring in, drugs 962t, 963–964
142–143, 144f biosynthesis of, 688, 688f cabazitaxel, 963
substitution on beta carbon in, 144 effects of, 691, 693f docetaxel, 962t, 963
types of, 154t in hypothalamic-pituitary-thyroid axis, eribulin, 963–964
Sympathoplegics, 176, 176f, 178–182 689, 691f ixabepilone, 963
adrenergic neuron-blocking agents, 191t mechanism of action of, 690–691, 693f paclitaxel, 962t, 963